Cardiovascular disease is a significant cause of death worldwide.
Current diagnostic methods are invasive and difficult to use, which can lead to misdiagnosis and delayed treatment.
This is where this week’s stock comes in….
BioSig Technologies Inc.
The global market for cardiovascular disease is expected to reach $480 billion by 2027. This growth is being driven by the following factors:
The increasing cases of cardiovascular disease.
The aging population.
The rising cost of healthcare.
BioSig Technologies Inc. is a medical technology company that is developing innovative solutions for the diagnosis and management of cardiovascular disease.
The company's flagship product is the BioSig CORE System, a cardiac monitoring system that uses advanced signal processing algorithms to provide real-time insights into the electrical activity of the heart.
The BioSig CORE System has the potential to revolutionize the way cardiovascular disease is diagnosed and managed.
The system is:
Non-invasive.
Easy to use.
Provides a wealth of information that can help physicians make more informed treatment decisions.
In addition to the BioSig CORE System, BioSig Technologies is also developing a number of other products, including:
A wearable cardiac monitor.
A software platform for the analysis of cardiac data.
The company is well-funded and has a strong management team. BioSig Technologies is poised to become a major player in the cardiovascular disease market.
6 reasons why you should keep an eye on BioSig Technologies Inc.
1. Company insiders are buying shares.
In the last 6 months, company insiders, including the CEO, CFO, and COO have all acquired shares of BioSig Technologies (NASDAQ: BSGM).
This is a bullish sign, as it suggests that the company's management team believes in the long-term prospects of the company.
2. Analysts are bullish on the stock.
In a recent research report, Taglich Brothers' analyst, John Nobile, assigned a $1.50 target and maintained coverage on BioSig Technologies (NASDAQ: BSGM). This is a positive sign, as it suggests that analysts believe the stock is undervalued.
3. The company has a strong partnership with the Cleveland Clinic.
BioSig Technologies recently signed a Master Research Agreement with the Cleveland Clinic to explore expanded applications for its Digital Signal Processing Technology. This is a significant partnership, as the Cleveland Clinic is one of the leading medical institutions in the world.
4. The company has a first-mover advantage in the non-invasive cardiac monitoring market.
BioSig Technologies' first product, the PURE EP™ System, is an FDA 510(k) cleared non-invasive class II device that provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. This is a unique product that has the potential to disrupt the cardiac monitoring market.
5. The market for non-invasive cardiac monitoring is growing rapidly.
The global electrophysiology market is expected to exceed more than US $16 billion by 2028 and is growing at a compound annual growth rate (CAGR) of 11.2%. This growth is being driven by the increasing prevalence of cardiovascular disease and the demand for more accurate and efficient diagnostic tools.
6. The stock is currently trading at a discount to its fair value.
According to Barchart.com pricing, if BioSig Technologies (NASDAQ: BSGM) climbs back to its 52 week high of $2.46 set on 1/5/22 after bouncing off of its 52 week low of $.2514 set on 11/09/2022, it would cap off a 878.52% move. This move is not expected to occur, but the potential should be noted.
As always, I recommend that you do your own research starting here.
Let's learn and earn together 💪!
Team Inspired Analyst - Signing off.
Disclaimer
This sponsored post references an opinion and is for information purposes only. It is not intended to be investment/financial advice. Seek a duly licensed professional for investment/financial advice. Please always do your research before investing as you are responsible for any capital-related decisions you make and only you are accountable for the results.